Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Mar 15, 2019

Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the Treatment of ROS1 Fusion-Positive Non-Small Cell Lung Cancer

  • An application was filed for ROS1 fusion-positive locally advanced or metastatic non-small cell lung cancer following the filing for NTRK fusion-positive locally advanced or metastatic solid tumors in December 2018 in Japan

TOKYO, March 15, 2019 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it filed a new drug application to the Ministry of Health, Labour and Welfare (MHLW) for a ROS1/TRK inhibitor entrectinib for the treatment of ROS1 fusion-positive non-small cell lung cancer (NSCLC).

“With the previous filing of NTRK fusion-positive solid tumors, which is a rare type of cancer, and ROS1 fusion-positive NSCLC, which accounts for one to two percent of NSCLC, Chugai wishes that entrectinib would become a new treatment option for these patients and we will continue working to contribute to the development of personalized medicine," said Dr. Yasushi Ito, Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit.

This application for approval is based on an integrated analysis of an open-label, multicenter, global phase II study (the STARTRK-2 study) and three overseas phase I studies (the STARTRK-NG study, the STARTRK-1 study and the ALKA-372-001 study). Efficacy was evaluated in 53 patients with ROS1 fusion-positive NSCLC while safety assessment was conducted with 355 patients registered in the four trials.

As the top pharmaceutical company in the field of oncology in Japan, Chugai will work to obtain early approval in order to provide entrectinib as a new treatment option for patients and medical professionals.

[Reference information]

About entrectinib
Entrectinib is an oral medicine in filling for approval for the treatment of locally advanced or metastatic solid tumors that harbor NTRK1/2/3 or ROS1 gene fusions. It is a selective, CNS-active tyrosine kinase inhibitor designed to inhibit the kinase activity of the TRK A/B/C and ROS1 proteins, whose activating fusions drive proliferation in certain types of cancer. Entrectinib can block ROS1 and NTRK kinase activity and inhibit proliferation of cancer cells with ROS1 or NTRK gene fusions. FDA has granted priority review for entrectinib for the treatment of NTRK fusion-positive solid tumors and ROS1 fusion-positive NSCLC.

About ROS1 fusion-positive NSCLC
ROS1 fusion gene is an abnormal gene that can be formed by fusing the ROS1 gene and other genes (CD74, etc.) as a result of chromosomal translocation for some reason. The ROS1 fusion kinase made from ROS1 fusion gene is thought to promote cancer cell proliferation. ROS1 fusion gene is found in about one to two percent of non-small cell lung cancer, among which it is more expressed in adenocarcinoma.


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail:
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail:
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top